Senti Biosciences heads into its May 6 earnings call with short sellers piling in at a pace not seen in months — and a fresh $40 million financing deal raising its own questions about dilution.
The short interest story this week is hard to ignore. At 4.7% of free float, the position itself is not extreme. But the pace of accumulation is: short interest more than doubled over the past week, up 116%, and has risen 48% over the past month. The sharpest move came in just two sessions — shares short jumped from roughly 451,000 on April 27 to over 1.2 million by April 30. The ORTEX short score hit 77 on April 30, up sharply from 38.7 just three days earlier on April 27, marking one of the fastest escalations in the score's recent history for this name.
Borrow conditions reflect the new demand. Cost to borrow climbed 42% over the week to reach 13.2% annually — elevated for a micro-cap biotech but not yet prohibitive. Availability has tightened noticeably: with availability sitting in the 77% range after briefly touching its 52-week tightest point of near zero availability on April 28 (when utilization briefly spiked to 98%), the lending market is under real pressure. That April 28 spike coincided directly with the day Senti's shelf offering registration became effective — the market appears to be pricing in near-term share supply.
The catalyst is now public. On May 1, Senti announced a convertible note financing agreement worth up to $40 million with an affiliate of Celadon Partners — already by far the largest shareholder at 31.4% of shares. The 8-K filing and a concurrent Form 424B5 prospectus supplement confirm the equity overhang is real. For a stock trading just above $1.00, any conversion scenario carries meaningful dilution risk. Short sellers, it appears, were positioning ahead of the announcement.
The Street is uniformly bullish on paper — every listed analyst carries a Buy or Outperform rating — but the targets tell a more nuanced story. Chardan Capital, the most consistent follower, trimmed its target from $13 to $11 in late March after maintaining it at $12 for over a year. Leerink Partners initiated coverage in November 2025 with an Outperform and a more conservative $6 target. All of those targets were set before the Celadon convertible deal and, with the stock at $1.02, remain far above the current price. The mean target of $11 implies enormous upside on paper, but the gap between analyst targets and the market price is a function of clinical risk and dilution uncertainty rather than an obvious mispricing. The bull case rests on SENTI-202, the company's off-the-shelf CAR-NK cell therapy for AML, and a gene circuit platform designed to target tumour cells with precision. The bear case is straightforward: limited cash, a convertible deal with a concentrated insider, and an uncertain regulatory path.
Recent earnings history adds another layer of caution. The last print on March 27 drove a 12.4% single-day decline, though the stock recovered to post a 3.5% gain over the following five days. The November 2025 release was worse on the day — down 14.8% — but that was followed by a 29.8% five-day rally. The pattern is volatile: sharp initial reactions, sometimes reversed. With the next event confirmed for May 6, the setup is a stock down 6% on the week, up 10% on the day before this note, with shorts freshly doubled and a convertible financing deal just disclosed.
What to watch on May 6 is less about the headline figures and more about how management frames the Celadon convertible structure — specifically the conversion terms, the use of proceeds, and any update on the SENTI-202 clinical timeline — against a borrow market that has been tightening all week.
See the live data behind this article on ORTEX.
Open SNTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
